Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339079 · ClinicalTrials.gov registry record · Phase 1
Treatment of Hypochondriasis With CBT and/or SSRI
A Phase 1 study of Hypochondriasis, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 195
- Enrollment target
- 2
- Study locations
NCT00339079 is a Phase 1 study of Hypochondriasis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 195 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00339079, a Phase 1 study of Hypochondriasis, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 195 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis.
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive Behavioral Therapy (CBT)
- DRUG Fluoxetine
- OTHER Supportive Therapy
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
New York
- Columbia Medical Center, New York Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00339079
The ClinicalTrials.gov registry entry for NCT00339079 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypochondriasis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00339079 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00339079 about?
NCT00339079 is a clinical study titled "Treatment of Hypochondriasis With CBT and/or SSRI". This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis.
What is the current status of trial NCT00339079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 195 participants. The study started on 2006-06. Estimated completion is 2011-12.
What conditions does trial NCT00339079 study?
This clinical trial studies the following conditions: Hypochondriasis.
What interventions are being tested in trial NCT00339079?
The interventions under investigation include: Placebo (DRUG), Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Fluoxetine (DRUG), Supportive Therapy (OTHER).
Who is sponsoring clinical trial NCT00339079?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00339079 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.